MedTrace Logo

Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

NCT00272480 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2021-08-25

No results posted yet for this study

Summary

To determine whether the use of two antiviral agents in combination will be better than placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I

Conditions

  • HTLV-I-associated Myelopathy

Interventions

DRUG

Zidovudine/lamivudine

DRUG

Placebos

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Graham P Taylor, FRCP · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-11-08
Primary Completion
2002-07-30
Completion
2002-07-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00272480 on ClinicalTrials.gov